Literature DB >> 2244770

Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy.

I R Reid1, S W Heap.   

Abstract

This study addresses the impact of clinical and biochemical factors on the bone density of patients receiving glucocorticoid therapy. Vertebral mineral density was measured by quantitative computed tomography in 35 patients aged 17 to 77 years who had received therapeutic glucocorticoid drugs for 0.1 to 22 years. The mean (+/- SEM) vertebral mineral density z score in the subjects was -1.7 +/- 0.2. z score was unrelated to underlying diagnosis, sex, or age but was significantly related to the duration of previous steroid therapy (r = -.38) and to the total cumulative glucocorticoid dose (r = -.50). The rate of change of bone density in 16 of these subjects followed up over a period of 12 months was -8.9% and was significantly greater in subjects taking more than 12.5 mg of prednisone per day. Bone loss was not influenced by sex, age, duration of previous steroid treatment, or diagnosis and was not predictable from biochemical measures of calcium metabolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2244770

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  30 in total

1.  Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Authors:  W F Lems; J W Jacobs; J W Bijlsma; G J van Veen; H H Houben; H C Haanen; M I Gerrits; H J van Rijn
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

2.  Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients.

Authors:  I R Reid; M C Evans; D J Wattie; R Ames; T F Cundy
Journal:  Osteoporos Int       Date:  1992-03       Impact factor: 4.507

Review 3.  Management of corticosteroid-induced osteoporosis: a clinician's perspective.

Authors:  S L Silverman
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 4.  Prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  F Eggelmeijer
Journal:  Pharm World Sci       Date:  1998-10

Review 5.  Osteoporosis and polypharmacy.

Authors:  M Gosch; M Jeske; C Kammerlander; T Roth
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

6.  Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis.

Authors:  W F Lems; W G Jacobs; J W Bijlsma; A Croone; H C Haanen; H H Houben; M I Gerrits; H J van Rijn
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

7.  Relationship between glucocorticoid-induced osteoporosis and vitamin D receptor genotypes.

Authors:  Yuming Li; Lin Xu; Lingxun Shen; Likai Yu; Lulu Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

Review 8.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

9.  Bone status in glucocorticoid-treated men and women.

Authors:  E S Leib; R Winzenrieth
Journal:  Osteoporos Int       Date:  2015-08-08       Impact factor: 4.507

Review 10.  Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.

Authors:  R N J de Nijs; J W G Jacobs; A Algra; W F Lems; J W J Bijlsma
Journal:  Osteoporos Int       Date:  2004-05-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.